ORION CORPORATION PRESS RELEASE
Orion publishes Interim Report for January–September 2021 on Wednesday 20 October 2021
Orion will publish Interim Report for January–September 2021 on Wednesday,
Webcast and conference call
A webcast and a conference call for analysts, investors and media will be held on Wednesday,
A link to the live webcast will be available on Orion's website at www.orion.fi/en/investors. A recording of the event will be available on the website later the same day.
To participate the conference call, please dial:
PIN: 49775482#
Silent period
The silent period preceding the publication is ongoing and continues until the disclosure.
Contact person:
tel. +358 10 426 2721
Publisher:
Communications
Orionintie 1A, FI-02200 Espoo,
www.orion.fi
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to
© OMX, source